Nanoantibodies based on conexin and panexin as new hemicanal inhibitors for the therapy of inflammatory diseases COPACABANA (Q3252312)

From EU Knowledge Graph
Revision as of 15:49, 18 December 2021 by DG Regio (talk | contribs) (‎Changed label, description and/or aliases in nl, and other parts: Adding Dutch translations)
Jump to navigation Jump to search
Project Q3252312 in Spain
Language Label Description Also known as
English
Nanoantibodies based on conexin and panexin as new hemicanal inhibitors for the therapy of inflammatory diseases COPACABANA
Project Q3252312 in Spain

    Statements

    0 references
    6,250.0 Euro
    0 references
    12,500.0 Euro
    0 references
    50.0 percent
    0 references
    1 January 2018
    0 references
    31 December 2018
    0 references
    PROTOQSAR 2000 SL
    0 references
    0 references

    39°28'10.96"N, 0°22'34.82"W
    0 references
    46250
    0 references
    El proyecto COPACABANA pretende introducir nano-anticuerpos elegibles para fines terapéuticos dirigidos contra Cx43, Cx32, Cx26 y Panx1, utilizando protocolos novedosos, incluida la inmunización con ADN de llamas combinada con tecnología de nano-discos. COPACABANA probará estos nano-anticuerpos por su potencial para inhibir los hemicanales y para aliviar las características patológicas en modelos en roedores de una variedad de enfermedades inflamatorias. (Spanish)
    0 references
    The COPACABANA eligible project aims to introduce nano-antibodies for therapeutic purposes directed against Cx43, Cx32, Cx26 and Panx1, using novel protocols including DNA immunization with combined flames nano-discs. COPACABANA test these nano-antibodies for their potential to inhibit hemichannels and to alleviate the pathological features in rodent models of a variety of inflammatory diseases. (English)
    0 references
    Le projet COPACABANA vise à introduire des nano-anticorps éligibles à des fins thérapeutiques ciblant les Cx43, Cx32, Cx26 et Panx1, en utilisant de nouveaux protocoles, y compris l’immunisation de l’ADN de flamme combinée à la technologie nanodisque. Copacabana testera ces nano-anticorps afin de déterminer leur potentiel d’inhibition des hémicanaux et d’atténuer les caractéristiques pathologiques dans les modèles de rongeurs de diverses maladies inflammatoires. (French)
    5 December 2021
    0 references
    Das COPACABANA-Projekt zielt darauf ab, Nanoantikörper einzuführen, die für therapeutische Zwecke in Frage kommen, die auf Cx43, Cx32, Cx26 und Panx1 abzielen, wobei neuartige Protokolle verwendet werden, einschließlich der Flammen-DNA-Immunisierung in Kombination mit Nanodisc-Technologie. Copacabana wird diese Nanoantikörper auf ihr Potenzial zur Hemmung von Hemikalien und zur Linderung pathologischer Eigenschaften in Nagetiermodellen verschiedener entzündlicher Erkrankungen testen. (German)
    10 December 2021
    0 references
    Het COPACABANA-project heeft tot doel nano-antilichamen te introduceren die in aanmerking komen voor therapeutische doeleinden gericht op Cx43, Cx32, Cx26 en Panx1, met behulp van nieuwe protocollen, waaronder vlam-DNA-immunisatie gecombineerd met nanodisc-technologie. Copacabana zal deze nano-antilichamen testen op hun potentieel om hemicanalen te remmen en pathologische kenmerken in knaagdiermodellen van een verscheidenheid van ontstekingsziekten te verlichten. (Dutch)
    18 December 2021
    0 references
    Valencia
    0 references

    Identifiers

    20F01020101U_IVCI00000APEA8025
    0 references